Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Elicio Therapeutics (ELTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Elicio Therapeutics (ELTX – Research Report) and BioCryst (BCRX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma (ASND)
In a report issued on January 8, Luca Issi from RBC Capital maintained a Buy rating on Ascendis Pharma, with a price target of $245.00. The company’s shares closed last Monday at $208.76.
According to TipRanks.com, Issi is a 1-star analyst with an average return of
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $267.58, representing a 31.6% upside. In a report issued on January 9, Evercore ISI also maintained a Buy rating on the stock with a $305.00 price target.
See the top stocks recommended by analysts >>
Elicio Therapeutics (ELTX)
According to TipRanks.com, Roy is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elicio Therapeutics with a $15.50 average price target.
BioCryst (BCRX)
RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst on January 8 and set a price target of $14.00. The company’s shares closed last Monday at $7.09.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $19.36 average price target, representing a 165.2% upside. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $18.00 price target.
